When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature

Critical Care Medicine

Volumn 34, Issue 11, 2006, Pages 2738-2747

  Talmor, Daniel ^a   Shapiro, Nathan ^a   Greenberg, Dan ^b   Stone, Patricia W ^c   Neumann, Peter J ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness analysis; Cost utility analysis; Critical care medicine; Intensive care unit; Quality adjusted life years; Sepsis

Indexed keywords

ACTIVATED PROTEIN C;

ACUTE RESPIRATORY FAILURE; ARTICLE; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DECISION MAKING; DISEASE SEVERITY; ECONOMIC EVALUATION; GENERAL PRACTICE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; SEPSIS; SYSTEMATIC REVIEW;

COST-BENEFIT ANALYSIS; CRITICAL CARE; HEALTH CARE COSTS; HUMANS; INTENSIVE CARE UNITS; QUALITY-ADJUSTED LIFE YEARS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 33750238031     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000241159.18620.AB     Document Type: Article

References (42)

1. Angus DC, Barnato AE, Linde-Zwirble WT, et al: Use of intensive care at the end of life in the United States: An epidemiologic study. Crit Care Med 2004; 32:638-643
2. Barnato AE, McClellan MB, Kagay CR, et al: Trends in inpatient treatment intensity among Medicare beneficiaries at the end of life. Health Serv Res 2004; 39:363-375
3. Halpern NA, Pastores SM, Greenstein RJ: Critical care medicine in the United States 1985-2000: An analysis of bed numbers, use, and costs. Crit Care Med 2004; 32:1254-1259
4. Mularski RA, Osborne ML: End-of-life care in the critically ill geriatric population. Crit Care Clin 2003; 19:789-810, viii
5. Gold M, Siegel J, Russel L, Weinstein M (Eds): Cost-effectiveness in Health and Medicine. New York, Oxford University Press, 1996
6. Coughlin MT, Angus DC: Economic evaluation of new therapies in critical illness. Crit Care Med 2003; 31(1 Suppl):S7-S16
7. Understanding costs and cost-effectiveness in critical care: Report from the second American Thoracic Society workshop on outcomes research. Am J Respir Crit Care Med 2002; 165:540-550
8. Neumann PJ, Greenberg D, Olchanski NV, et al: Growth and quality of the cost-utility literature, 1976-2001. Value Health 2005; 8:3-9
9. Federal Reserve Statistical Release, Foreign Exchange Rates. Available at: http://www.federalreserve.gov/releases/H10/hist/default.htm
10. US Department of Labor, Bureau of Labor Statistics: Consumer Price Indexes. Available at http://www.bls.gov/cpi/home.htm
11. Wenzel RP: The Lowbury Lecture: The economics of nosocomial infections. J Hosp Infect 1995; 31:79-87
12. Shields PL, Field J, Rawlings J, et al: Long-term outcome and cost-effectiveness of parenteral nutrition for acute gastrointestinal failure. Clin Nutr 1996; 15:64-68
13. Gopal I, Bhonagiri S, Ronco C, et al: Out of hospital outcome and quality of life in survivors of combined acute multiple organ and renal failure treated with continuous venovenous hemofiltration/hemodiafiltration. Intensive Care Med 1997; 23:766-772
14. Korkeila M, Ruokonen E, Takala J: Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care. Intensive Care Med 2000; 26:1824-1831
15. Earle CC, Chapman RH, Baker CS, et al: Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18:3302-3317
16. Stone PW, Schackman BR, Neukermans CP, et al: A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis 2005; 5:383-391
17. Neilson AR, Burchardi H, Chinn C, et al: Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 2003; 18:217-227
18. Angus DC, Linde-Zwirble WT, Clermont G, et al: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003; 31:1-11
19. Fowler RA, Hill-Popper M, Stasinos J, et al: Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 2003; 18:181-191; discussion, 191-184
20. Manns BJ, Lee H, Doig CJ, et al: An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:993-1000
21. Evans C, Tavakoli M, Crawford B: Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: A critical appraisal. Health Care Manage Sci 2004; 7:43-49
22. Herridge MS, Cheung AM, Tansey CM, et al: One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003; 348:683-693
23. Sassi F, Archard L, McDaid D: Searching literature databases for health care economic evaluations: How systematic can we afford to be? Med Care 2002; 40:387-394
24. Davies A, Ridley S, Hutton J, et al: Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Anaesthesia 2005; 60:155-162
25. Shorr AF, Susla GM, Kollef MH: Linezolid for treatment of ventilator-associated pneumonia: A cost-effective alternative to vancomycin. Crit Care Med 2004; 32:137-143
26. MacLaren R, Sullivan PW: Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health 2005; 8:105-116
27. Shorr AF: An update on cost-effectiveness analysis in critical care. Curr Opin Crit Care 2002; 8:337-343
28. Anon JM, Garcia de Lorenzo A, Zarazaga A, et al: Mechanical ventilation of patients on long-term oxygen therapy with acute exacerbations of chronic obstructive pulmonary disease: Prognosis and cost-utility analysis. Intensive Care Med 1999; 25:452-457
29. Hamel MB, Phillips RS, Davis RB, et al: Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. Am J Med 2000; 109:614-620
30. Hamel MB, Phillips RS, Davis RB, et al: Are aggressive treatment strategies less cost-effective for older patients? The case of ventilator support and aggressive care for patients with acute respiratory failure. J Am Geriatr Soc 2001; 49:382-390
31. Mayer SA, Copeland D, Bernardini GL, et al: Cost and outcome of mechanical ventilation for life-threatening stroke. Stroke 2000; 31:2346-2353
32. Wachter RM, Luce JM, Safrin S, et al: Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure. JAMA 1995; 273:230-235
33. Hamel MB, Phillips R, Teno J, et al: Cost effectiveness of aggressive care for patients with nontraumatic coma. Crit Care Med 2002; 30:1191-1196
34. Paniagua D, Lopez-Jimenez F, Londono JC, et al: Outcome and cost-effectiveness of cardiopulmonary resuscitation after in-hospital cardiac arrest in octogenarians. Cardiology 2002; 97:6-11
35. Marciante KD, Veenstra DL, Lipsky BA, et al: Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. Am J Infect Control 2003; 31:1-8
36. Fenton-Lee D, Imrie CW: Pancreatic necrosis: Assessment of outcome related to quality of life and cost of management. Br J Surg 1993; 80:1579-1582
37. Hamel MB, Phillips RS, Davis RB, et al: Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults: SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med 1997; 127:195-202
38. Kerridge RK, Glasziou PP, Hillman KM: The use of "quality-adjusted life years" (QALYs) to evaluate treatment in intensive care. Anaesth Intensive Care 1995; 23:322-331
39. Smith KJ, Pesce RR: Pulmonary artery catheterization in exacerbations of COPD requiring mechanical ventilation: A cost-effectiveness analysis. Respir Care 1994; 39:961-967
40. Sznajder M, Aegerter P, Launois R, et al: A cost-effectiveness analysis of stays in intensive care units. Intensive Care Med 2001; 27:146-153
41. Schapira DV, Studnicki J, Bradham DD, et al: Intensive care, survival, and expense of treating critically ill cancer patients. JAMA 1993; 269:783-786
42. Heyland DK, Konopad E, Noseworthy TW, et al: Is it 'worthwhile' to continue treating patients with a prolonged stay (>14 days) in the ICU? An economic evaluation. Chest 1998; 114:192-198